Hypofractionated radiation therapy for localized prostate cancer (first experience)
- Autores: Vorob'eva T.G1, Bednyj I.V1, Drobjazgin E.A1,2, Polovnikov E.S1
-
Afiliações:
- Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy
- Novosibirsk State Medical University
- Edição: Nº 1 (2016)
- Páginas: 70-74
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/282353
- ID: 282353
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
This paper presents a study of 74 prostate cancer patients divided into 2 groups (study group and comparison group). The comparison group patients (n=50) were treated with radiation therapy in standard fractionated mode, while study group patients (n=24) underwent hypofractionated radiation therapy (STD 7.5 Gy; TTD 37.5 Gy). Early radiation-induced complications occurred only in the comparison group patients. Late radiation-induced complications were observed in 4 and 8 patients in the study group and the comparison group, respectively. Significant statistic differences in quality of life between groups were found in patients with excellent (FET; p=0.0145) and satisfactory (FET; p=0.03) well-being. Hypofractionated radiation therapy is safe given that the necessary technical and clinical conditions are observed. It significantly reduces treatment time and enables quickly bringing a course of radiation therapy to radical doses. This is a noninvasive treatment that significantly reduces risks and cost of procedures.
Palavras-chave
Texto integral
Sobre autores
T. Vorob'eva
Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy
I. Bednyj
Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy
Email: p_filatov@nricp .ru
E. Drobjazgin
Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy; Novosibirsk State Medical University
Email: evgenyidrob@inbox.ru
E. Polovnikov
Academician E.N. Meshalkin Novosibirsk State Research Institute of Circulation Pathology, Center of Oncology and Radiotherapy
Email: drojo@mail.ru
Bibliografia
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и в странах СНГ в 2012 году. М.: Издательская группа РОНЦ. 2014. 226 с
- Freeman D.E., King C.R. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiation Oncology. 2011; 6:3.
- Katz A.J., Santoro M., Ashley R., Katz A.J., Santoro M., Ashley R. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol. Cancer Res. Treat. 2010;9(6):575-582.
- Lukka H., Hayter C., Julian J.A., Lukka H., Hayter C., Julian J.A. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J. Clin. Oncol. 2005;23(25):6132-6138.
- McBride S.M., Wong D.S., Dombrowski J.J., Harkins B., Tapella P., Hanscom H.N., Collins S.P., Kaplan I.D. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118(15):3681-3690.
- Alongi F., Cozzi L., Arcangeli S., Iftode C., Comito T., Villa E., Lobefalo F., Navarria P., Reggiori G., Mancosu P., Clerici E., Fogliata A., Tomatis S., Taverna G., Graziotti P., Scorsetti M. Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology. 2013; 8: 171.
Arquivos suplementares
